Samsung BioLogics signed supply contract with Saint-Gobain
- Signed a supply contract for the single-use system products with Saint-Gobain
- “Enhancing CDMO capabilities by stabilizing supply chain”
2018. 12. 05(wed)
Photo: Taehan Kim, the CEO of Samsung Biologics and Laurent Guillot, the CEO of HIGH-PERFORMANCE Materials Division, Saint Gobain
Incheon, South Korea, December 5th, Samsung BioLogics announced today that the company signed the supply contract for single-use system products with Saint-Gobain, a French based global company, at Samsung BioLogics’ headquarter in Songdo on Tuesday December 4th.
According to the agreement, Saint-Gobain will supply a maximum of 160 kinds of single-use system products, including tubing, filter, and hose for the biopharmaceutical production of Samsung BioLogics.
Samsung BioLogics has been used single-use system products for the small volume production. Because the single-use systems were supplied from over sea, it took long time for imports and custom clearance. Through this contract, domestic supply of single-use systems became possible, shortening the procurement period from four months to one month.
Samsung BioLogics has negotiated supply of single-use system products with Saint-Gobain, which notably provides high-performance products and services for the Life Sciences market, from April 2018. Saint-Gobain decided to establish a production facility based at Songdo in September and the final supply contract was concluded. Construction of the facility will be completed in 2020.
Songdo, where Samsung BioLogics and Celltrion is located, became the largest biopharmaceutical manufacturing city with 560K liters of bioreactor capacity upon the completion of Samsung BioLogics’ Plant 3.
“Through partnership with Samsung BioLogics, Saint-Gobain is strengthening its customer-centric development and supply chain capabilities to better serve the biopharmaceutical and medical industries in Korea. We are excited to play a key role in the advancement of the bio cluster ecosystem in Korea”, said Laurent Guillot, Senior Vice President of Saint-Gobain, CEO of High Performance Solutions.
Tae Han Kim, the president and CEO of Samsung BioLogics, said "Samsung Biologics will gain more competitiveness in order to supply its products to customers faster and at lower prices with customized bio fluid systems that is flexible according to products." He added "Samsung Biologics, as the world's leading CMO, will continue to lead the growth of Songdo Bio-Cluster in the future for the development of Korea bio-industry."
- The End -